Received: from mta4.rcsntx.swbell.net (mta4-pr.rcsntx.swbell.net [151.164.60.117])
by mail1.rcsntx.swbell.net (8.9.3/8.9.3) with ESMTP id QAA08211;
Mon, 1 Nov 1999 16:25:42 -0600 (CST)
Received: from madhatter.morelli.com ([216.89.218.3]) by mta4.rcsntx.swbell.net
(Sun Internet Mail Server sims.3.5.1999.09.16.21.57.p8)
with ESMTP id <[log in to unmask]>; Mon,
1 Nov 1999 16:25:41 -0600 (CST)
Received: (from majordomo@localhost) by madhatter.morelli.com (8.8.8/8.8.8)
id VAA25703; Mon, 01 Nov 1999 21:58:55 +0000 (GMT)
Date: Mon, 01 Nov 1999 15:57:52 -0600
From: WE MOVE <[log in to unmask]>
Subject: Entacapone Approved by FDA
Sender: [log in to unmask]
To: [log in to unmask]
Message-id: <[log in to unmask]>
Precedence: bulk
X-MimeOLE: Produced By Microsoft MimeOLE V4.72.3110.3
X-Authentication-warning: madhatter.morelli.com: majordomo set sender to
[log in to unmask] using -f
The United States Food and Drug Administration has approved the marketing
of the COMT inhibitor entacapone (Comtan, Novartis) as an adjuct to
levodopa/carbidopa for treatment of Parkinson's disease.
The FDA-approved product labeling information is available at
http://www.fda.gov/cder/approval/index.htm (find "Comtan" and click on the
link under the "Label" heading to download a .pdf file).
Copyright 1999 WE MOVE
Editor: Richard Robinson ([log in to unmask])
E-MOVE archives, plus information on subscribing, are
available at http://www.wemove.org/emove.
To unsubscribe, send an e-mail to [log in to unmask],
with "unsubscribe e-move" in the message body.
E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for
Movement Disorders)
204 West 84th Street
New York, NY 10024
TEL 800-437-MOV2
TEL 212-241-8567
FAX 212-987-7363
http://www.wemove.org
